Lyumjev

Approved Uses

Lyumjev is a prescription medication indicated for the treatment of diabetes. It is used to manage blood glucose levels in the following populations:

• Adults: For the treatment of both type 1 and type 2 diabetes.
• Children: For the treatment of both type 1 and type 2 diabetes.

As a fast-acting insulin, Lyumjev is specifically designed to control the rise in blood sugar that occurs after eating. It is typically administered at the beginning of a meal or within 20 minutes after starting a meal.

How It Is Administered

This medication is used in several ways depending on a patient's specific treatment plan:

• Daily subcutaneous (under the skin) injections.
• Continuous subcutaneous infusion using an external insulin pump.
• Intravenous infusion, which is performed by healthcare professionals in a clinical setting.

Regulating Blood Sugar

The primary role of Lyumjev is to regulate glucose (sugar) metabolism in the body. Like natural insulin, it lowers blood sugar levels through two main actions:

• Glucose Uptake: It signals cells in the body, particularly skeletal muscle and fat cells, to absorb sugar from the bloodstream so it can be used for energy.
• Inhibiting Sugar Production: It tells the liver to stop producing and releasing more sugar into the blood.

Ultra-Rapid Absorption

Lyumjev is a formulation of insulin lispro that includes specific ingredients to make it work faster than standard rapid-acting insulins. It contains treprostinil and citrate, which help the insulin enter the bloodstream more quickly after an injection:

• Treprostinil helps widen the blood vessels at the site of the injection.
• Citrate increases the permeability of the local blood vessels.

Together, these additions allow the insulin to be absorbed rapidly, which helps manage the sharp rise in blood sugar that typically occurs after eating a meal. Because it enters the blood so quickly, it more closely matches the way a person without diabetes releases insulin in response to food.

Common Side Effects

The most frequently reported side effects of Lyumjev include:

• Low blood sugar (hypoglycemia): This is the most common side effect. Symptoms may include dizziness, sweating, confusion, headache, and hunger.
• Injection site reactions: Pain, redness, swelling, or itching where the medication was injected.
• Skin changes: Thickening or pitting of the skin at the injection site (lipodystrophy) or localized skin swelling (amyloidosis).
• Weight gain.
• Itching or rash.

Serious Side Effects

While less common, some side effects can be severe and require immediate medical attention:

• Severe hypoglycemia: Extremely low blood sugar can lead to seizures, loss of consciousness, or death if not treated promptly.
• Severe allergic reactions: Symptoms may include a whole-body rash, difficulty breathing, fast heartbeat, or swelling of the face, lips, or tongue.
• Low potassium (hypokalemia): Insulin can cause potassium levels in the blood to drop, which may lead to muscle cramps, abnormal heart rhythms, or fatigue.
• Heart failure: When used in combination with certain other diabetes medications called thiazolidinediones (TZDs), new or worsening heart failure may occur.

Hypoglycemia

Hypoglycemia, or low blood sugar, is the most common side effect of insulin therapy and can be life-threatening. Severe cases may lead to seizures, loss of consciousness, or death. Blood glucose monitoring is essential for all patients using insulin. Changes in insulin dose, meal patterns, physical activity, or co-administered medications may increase the risk of hypoglycemia.

Hypersensitivity Reactions

Severe, life-threatening allergic reactions, including anaphylaxis, can occur with Lyumjev. Symptoms may include a generalized rash, shortness of breath, wheezing, fast pulse, or sweating. If a serious reaction occurs, the medication should be stopped immediately and medical assistance sought.

Hypokalemia

All insulin products, including Lyumjev, cause a shift in potassium levels that can lead to hypokalemia (low blood potassium). If left untreated, low potassium can cause respiratory paralysis, heart rhythm abnormalities, and death. Monitoring potassium levels is recommended for patients at risk, such as those using potassium-lowering medications.

Fluid Retention and Heart Failure

The use of thiazolidinediones (TZDs) in combination with insulin may cause fluid retention and heart failure. Patients should be monitored for signs of heart failure, such as:

• Shortness of breath
• Swelling of the ankles or feet
• Sudden weight gain

Medication Errors and Sharing

To avoid medication errors, the insulin label must always be checked before each injection to ensure the correct product is being used. Additionally, Lyumjev prefilled pens, cartridges, or reusable pens must never be shared between patients, even if the needle is changed. Sharing these devices poses a risk for transmitting bloodborne pathogens.

Insulin Pump Risks

When Lyumjev is administered via an external insulin pump, malfunctions in the pump or infusion set can lead to a rapid rise in blood sugar and ketoacidosis. Patients using a pump must be trained to recognize these issues and have an alternative insulin delivery method, such as a syringe and vial, available at all times.

Pregnancy

Maintaining stable blood sugar levels is vital during pregnancy. Uncontrolled diabetes can lead to serious complications, including birth defects, stillbirth, and maternal high blood pressure (preeclampsia). Research on insulin lispro products has not shown a significant increase in the risk of major birth defects or miscarriage compared to the general population.

Insulin needs often fluctuate during pregnancy. Most people require less insulin during the first trimester and significantly more during the second and third trimesters. Healthcare providers typically monitor blood sugar closely and adjust dosages as needed throughout the pregnancy and immediately after delivery.

Breastfeeding

There is limited information regarding the presence of insulin lispro-aabc in human breast milk or its effects on a breastfed infant. However, insulin is naturally present in breast milk, and the medication is generally considered compatible with nursing. Dose adjustments and nutritional changes may be necessary for those who are breastfeeding to account for changes in metabolism and milk production.

Available Forms

Lyumjev is a clear, colorless liquid solution for injection. It is available in the following delivery systems:

• Vials: Multiple-dose containers for use with a syringe or an external insulin pump.
• Prefilled Pens: Disposable, single-patient-use pens, including the KwikPen, Junior KwikPen, and Tempo Pen.
• Cartridges: For use in compatible reusable delivery devices.

This medication can be administered via subcutaneous injection, continuous subcutaneous infusion through an insulin pump, or intravenous infusion performed by a healthcare professional.

FDA Approval Status

Lyumjev (insulin lispro-aabc) was approved by the U.S. Food and Drug Administration (FDA) in June 2020. It is classified as a rapid-acting human insulin analog designed to lower blood glucose levels.

Approved Indications

The FDA has approved Lyumjev for the following uses:

• To improve glycemic control in adults with type 1 or type 2 diabetes mellitus.
• To improve glycemic control in pediatric patients with type 1 or type 2 diabetes mellitus.

Regulatory History and Safety

Since its initial approval for adults, the FDA expanded the indication to include pediatric patients. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this medication. Regulatory oversight focuses on standard insulin safety concerns, including the risk of hypoglycemia and hypokalemia.

Factors Influencing Cost

The price you pay for Lyumjev can vary based on several elements:

• Insurance Coverage: Most commercial insurance plans and many Medicare Part D plans cover Lyumjev. Your specific out-of-pocket cost will depend on your plan's formulary, deductible, and copay tiers.
• Product Type: Lyumjev is available in 10 mL vials and 3 mL prefilled pens, including the KwikPen, Junior KwikPen, and Tempo Pen. The cost may differ depending on which delivery method is prescribed.
• Pharmacy Choice: Prices can fluctuate between different retail pharmacies, and mail-order services may offer different pricing for 90-day supplies.

Financial Assistance

Because Lyumjev is a brand-name medication without a direct generic equivalent, the manufacturer may offer savings cards or patient assistance programs. These programs are typically designed to help reduce costs for eligible individuals with commercial insurance or those who are uninsured and meet certain income requirements.

Generic Availability

There is currently no generic version of insulin lispro-aabc. While generic versions of standard insulin lispro exist, they are not the same as the ultra-rapid-acting Lyumjev formulation and cannot be automatically substituted at the pharmacy.